Tumor staging (TNM) and immunohistochemistry (IHC) are established predictors of breast cancer (BC) prognosis, but there are modulations by the tumor microenvironment and serum factors.
This study aims to evaluate circulating chemokines, cytokines and leukocytes in the blood of patients with BC.
